Novel Platform for Autologous Cell Therapy
Cancer patients – all of them – have a powerful, natural source of tumor-targeting immune cells that can fight cancer. WindMIL is the only company that can activate and expand these naturally occurring cells into marrow-infiltrating lymphocytes (MILs™), transforming them into a novel, next-generation cancer-fighting cell therapy.
Our scientific founders discovered that the bone marrow of cancer patients holds a natural reservoir of memory T cells that can recognize, find and eliminate cancer cells. Our technology collects, activates and expands these memory T cells into MILs, creating a flexible, scalable, wide-ranging, transformative platform for autologous cell therapy.
Collecting bone marrow containing these memory T cells is straightforward and completed via a short outpatient procedure. From this, WindMIL uses a standardized, patent-protected activation and expansion process to create therapeutic MILs quickly and efficiently.